AI search report

See where FOXO is losing buyers in AI search

See when AI mentions FOXO, where buyer questions leave you out, and what to fix first so more buyers discover you before competitors.

What buyers see in AI search

What AI says before buyers reach FOXO's site

FOXO shows up in

33%

FOXO appears in 0% of buyer questions and 100% of direct comparison questions that include FOXO. Medgenome appears in 33% of buyer questions.

Buyer questions missed

67%

FOXO is left out of 67% of the buyer and comparison questions checked.

Who AI recommends instead

Medgenome

Medgenome is the competitor AI surfaces most often here.

Where AI already picks you

AI does not consistently connect FOXO with a clear reason buyers would choose it yet. That usually means the evidence buyers need is either missing, scattered, or easier to find on competitor sites.

Where competitors beat you

  • Competitors beat FOXO on Biomarker Panel Testing. Xcode Life is rated moderate while FOXO is limited.
  • Competitors beat FOXO on Dna Testing Capabilities. Mapmygenome is rated strong while FOXO is limited.
  • Competitors beat FOXO on Genetic Variant Analysis. Mapmygenome is rated strong while FOXO is limited.

How AI describes you vs competitors

What AI connects each brand with

What buyers care aboutWhat this meansFOXOMedgenomeXcode LifeMapmygenome
Dna Testing CapabilitiesAI gives Mapmygenome more credit for dna testing capabilities than FOXO.Barely associatedBarely associatedBarely associatedClearly associated
Telomere Length AnalysisAI gives Medgenome more credit for telomere length analysis than FOXO.Barely associatedClearly associatedSometimes associatedBarely associated
Epigenetic Age AssessmentAI has little clear evidence connecting FOXO with epigenetic age assessment.Barely associatedBarely associatedBarely associatedBarely associated
Genetic Variant AnalysisAI gives Mapmygenome more credit for genetic variant analysis than FOXO.Barely associatedSometimes associatedBarely associatedClearly associated
Biomarker Panel TestingAI gives Xcode Life more credit for biomarker panel testing than FOXO.Barely associatedBarely associatedSometimes associatedBarely associated
Inflammation MarkersAI gives Mapmygenome more credit for inflammation markers than FOXO.Barely associatedBarely associatedBarely associatedSometimes associated

Buyer questions you are missing

The questions where buyers may never see FOXO

These are high-intent questions where AI did not mention FOXO. Each one can become a clear answer page AI can trust and reuse, supported by evidence from FOXO's site.

Buyer question

best DNA testing for longevity and aging markers in India

FOXO was not mentioned in this AI answer.

See the AI answer

Buyer question

how to check my biological age and get personalized anti-aging recommendations

FOXO was not mentioned in this AI answer.

See the AI answer

Buyer question

affordable precision health diagnostics platform for preventive wellness India

FOXO was not mentioned in this AI answer.

See the AI answer

Buyer question

biomarker testing service to optimize health and performance metrics

FOXO was not mentioned in this AI answer.

See the AI answer

Buyer question

comprehensive aging assessment and longevity planning tools online

FOXO was not mentioned in this AI answer.

See the AI answer

Buyer question

AI-powered health diagnostics for extending healthspan and lifespan

FOXO was not mentioned in this AI answer.

See the AI answer

What to fix first

The shortest path to better AI search presence

Readable turns missed buyer questions into pages AI can trust, clearer evidence buyers can verify, and comparison answers that make it easier for AI tools to recommend you.

1

Close the Biomarker Panel Testing gap before competitors keep winning the recommendation.: Buyers are asking about Biomarker Panel Testing, but your homepage barely explains it. AI answers currently connect Xcode Life more strongly with that need.

2

Secure mentions in foundational buyer queries by creating cited content on epigenetic age assessment, telomere length analysis, and biomarker panels—target InsideTracker and Humanity comparison pages where FOXO currently absent

3

Develop comparison landing pages explicitly positioning FOXO's FOXO gene variant specialization against Medgenome's clinical-grade breadth and Xcode Life's lifestyle integration to capture high-intent comparison traffic

4

Build partnerships with health publications and genetic testing review sites to establish FOXO as the cited authority for longevity-specific genetic analysis, moving beyond comparison-only visibility to foundational category recommendations

5

FOXO is completely absent from 6 buyer intent queries covering biological age checking, affordable diagnostics, biomarker optimization, and AI-powered healthspan extension—gaps where Medgenome and international platforms (InsideTracker, Humanity) are recommended

What you’ll see in the AI search review

Find the AI answers costing you buyers

In one review, we’ll show where FOXO is missing, which competitors AI is recommending instead, and the first pages or evidence updates most likely to help you show up.

1

The buyer questions where FOXO is left out.

2

The competitor claims AI is repeating instead.

3

The first fixes most likely to help FOXO show up.

Fix the buyer moments AI is missing

We’ll show you which AI answers are costing you buyers and what to publish first.

Bring this report to a short review with Readable. You will leave knowing the buyer questions, evidence gaps, and answer pages that matter most.

Improve my AI visibility